1. To understand the similarity between both types of IBD regarding structural and functional damage
2. To review the risk of intestinal cancer in both types of IBD
3. To review the prevalence of extra-intestinal manifestations (EIMs) in both Crohn's disease and ulcerative colitis
4. To emphasise the impact that both UC and CD can have on patient's life (quality of life, disability, fatigue, anxiety/depression, work productivity)
5. To have an overview of the economic burden of IBD in 2021

1. To understand the background and benefits of Patient centered care

2. To review the evidence of Patient centered care

3. To learn about both benefits and disadvantages with patient involvement when developing guidelines

Dr. Neeraj Narula reports a post-hoc analysis of the UNITI Crohn’s trials showing that early measurement of faecal calprotectin after induction therapy predicts clinical outcomes better than baseline measurements of calprotectin and than other week 6 clinical or biomarker data.

To provide a brief overview of the role of nutrition, diet and the dietitian in fertility, conception and pregnancy.

Educational objective:

-        To analyse Th17 plasticity in T-cell transfer colitis mouse model, and correlate this with the microbiota composition.

-        To understand whether antibiotics affect Th17 plasticity through microbiota-dependent processes.

Summary. During Inflammatory Bowel Disease (IBD), CD4+ effector T cells are main mediators of the tissue damage. Among them, Th17 cells strongly contribute to the inflammatory response. Interestingly, our lab previously showed that Th17 cells can convert into regulatory T cells, thereby controlling inflammation. However, the forces controlling the plasticity of T cells during IBD remain largely unknown. Our aim is to understand, how CD4+ T-cell plasticity can be modulated from a pro-inflammatory towards an anti-inflammatory profile during IBD. In this regard, both Th17 and Foxp3 regulatory T cells can recognize microbiota-antigens. Moreover, changes in the microbiota are commonly observed in IBD. Therefore, we hypothesize that the microbiota might be a key candidate to modulate T-cell plasticity. To address our goal, T-cell transfer mouse IBD model was performed by transferring CD4+ naïve T-cells into Rag1-/- mice. To study Th17 T-cell plasticity, we used as donors IL-17A Fate-mapping mice. Ciprofloxacin and metronidazole, antibiotics commonly given to IBD patients, were used to treat the mice. After T-cell transfer colitis induction, ciprofloxacin and metronidazole treatment ameliorated gut inflammation. In line with this, we observed a relative expansion of bacteria previously associated with beneficial IBD outcomes (e.g. Bifidobacterium). More interestingly, colon CD4+ T-cells showed an increased conversion from Th17 towards a Foxp3+ Treg profile (Foxp3ExTh17)(p=0.03).

The presentation will provide an update on the recently updated ECCO guideline on the prevention, diagnosis and management of infections in IBD

1. To understand the role of head to head trials in positioning therapies

2. To be familiar with the large pipeline of new agents for IBD including the late stage products focused on JAK inhibition, anti-p19 (interleukin 23) antibodies, and S1P modulators

3. To be familiar with the multiple agents targeting gut delivery that in early stage development

4. To be familiar with the evolving role of precision medicine and artificial intelligence in the care of IBD patients

5. To be familiar with novel clinical trial approaches are increasingly being employed in IBD including adaptive design, umbrella trials, basket trials, and platform trials